Immune thrombocytopenia
RecruitingStudy on the Safety and Effectiveness of Belantamab Mafodotin for Adults with Primary Immune Thrombocytopenia Previously Treated with Standard Medications
Study on the Safety and Effectiveness of Belantamab Mafodotin for Adults with Primary Immune Thrombocytopenia Previously Treated with Standard Medications
- Disease:Immune thrombocytopenia
- Substances:Belantamab Mafodotin
Greece- Participants:18–64 years · 65+ years
- Substances:Belantamab Mafodotin
- Sponsor:Hellenic Society Of Hematology











